Results 21 to 30 of about 303,717 (280)

Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update [PDF]

, 2022
Background: Targeting interleukin (IL)-6 has become a major therapeutic strategy in the treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies or by ...
Aletaha, Daniel, Takeuchi, Tsutomu, van der Heijde, Desiree, Sattar, Naveed, Winthrop, Kevin L, Voshaar, Marieke, Kerschbaumer, Andreas, Nash, Peter, Trauner, Michael, McInnes, Iain B, Stamm, Tanja A, Dougados, Maxime, Ravelli, Angelo, Kastrati, Kastriot, Dejaco, Christian, et al.   +15 more
core   +4 more sources

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy

Современная ревматология
Objective: to investigate the efficacy and safety of olokizumab (OKZ) in patients with rheumatoid arthritis (RA) over a 12-month period after switching from interleukin (IL)-6 receptor inhibitors (iIL6R) for non-medical reasons.Material and methods.
P. A. Shesternya, A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Yu. Yu. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, A. A. Blinova, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, N. V. Yudina, E. N. Alekseev, E. L. Nasonov, A. M. Lila   +17 more
doaj   +2 more sources

In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor [PDF]

Bioscience, Biotechnology, and Biochemistry, 2021
ABSTRACT Interleukin-6 (IL-6) binds to the IL-6 receptor (IL-6R) subunit, related to autoimmune diseases and cytokine storm in COVID-19. In this study, we performed systematic evolution of ligands by exponential enrichment and identified a novel RNA aptamer. This RNA aptamer not only bound to IL-6R with a dissociation constant of 200 n m,
Ando, Takehiro, Yamamoto, Mizuki, Takamori, Yukio, Tsukamoto, Keita, Fuji, Daisuke, Kawakami, Takashi   +5 more
openaire   +2 more sources

The Role of Interleukin-6 Inhibitors in the Treatment of COVID-19 Infections: A Case Series. [PDF]

Cureus, 2020
An outbreak of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection started in December 2019 in China that resulted in a global health emergency. The World Health Organization later named the disease as coronavirus disease 2019 (COVID-19).
Tadepalli S, Vanjarapu JMR, De Dona A, Cheriyath P, Nookala V.   +4 more
europepmc   +4 more sources

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)

Научно-практическая ревматология, 2022
Rheumatoid arthritis (RA) is a chronic immune-mediated rheumatic diseases (IMRDs) manifested with progressive destruction of joints, systemic inflammation of visceral organs and a wide range of co-morbidities associated with chronic inflammation.
E. L. Nasonov, E. Feist
doaj   +1 more source

Assessment of Clinical Efficacy of Dexamethasone in Patients with Moderate COVID-19

Общая реаниматология, 2022
The host immune response, primarily manifested by hypercytokinemia, obviously plays a key role in the development of severe novel coronavirus disease, COVID-19.
M. V. Tolochko, I. N. Leyderman, O. A. Khokhunov, V. A. Mazurok, R. E. Rzheutskya   +4 more
doaj   +1 more source

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy

Frontiers in Oncology, 2022
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs)
Sebastian Bruera, Maria E. Suarez-Almazor   +1 more
doaj   +1 more source

Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis

Frontiers in Medicine, 2020
Sarcoidosis is a multisystem granulomatous disease of unknown origin that has variable clinical course and can affect nearly any organ. It has a chronic course in about 25% of patients.
Gonçalo Boleto, Gonçalo Boleto, Matheus Vieira, Matheus Vieira, Anne Claire Desbois, Anne Claire Desbois, Anne Claire Desbois, Anne Claire Desbois, Anne Claire Desbois, David Saadoun, David Saadoun, David Saadoun, David Saadoun, David Saadoun, Patrice Cacoub, Patrice Cacoub, Patrice Cacoub, Patrice Cacoub, Patrice Cacoub   +18 more
doaj   +1 more source

Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients

Frontiers in Immunology, 2020
In December 2019, following a cluster of pneumonia cases in China caused by a novel coronavirus (CoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection disseminated worldwide and, on March 11th, 2020, the World Health ...
Serena Colafrancesco, Rossana Scrivo, Cristiana Barbati, Fabrizio Conti, Roberta Priori   +4 more
doaj   +1 more source

Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19 patients with hyperinflammatory response; however, there is a lack of systematic review directly evaluating their efficacy and safety.Objective: This review was ...
Jin Zhang, Jin Zhang, Xiongxiong Fan, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Dong Liu, Dong Liu   +9 more
doaj   +1 more source